Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 Settembre;45(3) > The Quarterly Journal of Nuclear Medicine 2001 Settembre;45(3):231-4

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  PET IN ONCOLOGY
Guest Editor: I. Carrio


The Quarterly Journal of Nuclear Medicine 2001 Settembre;45(3):231-4

lingua: Inglese

PET in lung cancer staging

Coleman R. E.

From the Department of Radiology Duke University Medical Center Durham, North Carolina, USA


FULL TEXT  


The pri­mary clin­i­cal appli­ca­tion of FDG-PET is in the eval­u­a­tion of ­patients ­with ­lung can­cer and ­includes diag­no­sis, stag­ing and restag­ing of non-­small ­cell ­lung can­cer. PET has a ­very ­high accu­ra­cy (sen­si­tiv­ity = 97%, spec­i­fic­ity = 78%) for char­ac­ter­iz­ing nod­ules ­that are inde­ter­mi­nate by ­chest radio­graph and com­put­ed tomog­ra­phy. The ­major util­ity of PET in the eval­u­a­tion of ­patients ­with ­lung can­cer is the stag­ing of the ­entire ­body. PET is ­more accu­rate ­than the con­ven­tion­al imag­ing modal­ities of CT and ­bone ­scans in the detec­tion of met­a­stat­ic dis­ease. PET is accu­rate in the stag­ing of the med­i­as­ti­num, adren­al ­glands, and the skel­e­tal ­system. PET is not as accu­rate in the detec­tion of ­brain metas­ta­ses ­because of ­their ­small ­size and the nor­mal cor­ti­cal accu­mu­la­tion.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail